Efficacy of recombinant human endostatin combined with vinorelbine-cisplatin regimen in newly diag-nosed patients with advanced non-small cell lung cancer patients with bone metastases and the impact on expression of serum VEGF / 实用肿瘤学杂志

ABSTRACT

Objective To explore the efficacy of recombinant human endostatin ( Rh-endostatin ) com-bined with vinorelbine -cisplatin( NP) regimen for newly diagnosed patients with advanced non -small cell lung cancer(NSCLC)with bone metastases and the impact on expression of serum vascular endothelial growth factor (VEGF).Methods From January 1,2009 to February 1,2012,a total of 40 with newly diagnosed,advanced NSCLC patients with bone metastases were enrolled in this study and randomly assigned to the treatment (N=20) or control(N=20)group.The control group was only given the NP regimen chemotherapy and the treatment group was treated with Rh-endostatin combined with NP regimen .The changes in clinical effects of the two groups and serum VEGF levels were observed .Results After two cycles of systemic chemotherapy ,objective response rate (ORR)and disease control rate(DCR)of the treatment group were 30.0% and 80.0%significantly higher than 5.0%and 45.0%of the control group(P0.05).Conclusion Rh-endostatin combined with NP regimen can im-prove the efficiency of treatment for newly diagnosed patients with advanced NSCLC with bone metastases and does not increase adverse reactions whereas no significant difference in serum VEGF Levels .